राइनो-ऑर्बिटल-सेरेब्रल म्यूकोर्मिकोसिस CNS भागीदारी के साथ: सैल्वेज प्रोटोकॉल जब प्रथम-पंक्ति थेरेपी स्थिर या आंशिक प्रतिक्रिया प्राप्त करने में विफल हो

References

• In CNS involvement, animal models and the above observations support use of liposomal amphotericin B at 10 mg/kg per day.
• Isavuconazole is strongly supported as salvage treatment.
• Posaconazole delayed release tablets or infusions are strongly supported for salvage treatment, and when available should be preferred over posaconazole oral suspension, which in turn is marginally supported for salvage treatment.
• In cases of primary treatment failure with isavuconazole or posaconazole, the guideline group supports recommendations for all three lipid-based amphotericin B formulations with strong to moderate strength.
• In case of extensive disease, rapid progression, or poor general condition, the addition of isavuconazole or posaconazole can be considered.
• Treatment should be continued until resolution of initially indicative findings on imaging and reconstitution of host immune system.